Synairgen plc

Equities

SNG

GB00B0381Z20

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 03:27:23 17/07/2024 pm IST			5-day change	1st Jan Change
4.87 ^GBX	+0.41%		-2.50%	-18.49%

27/06	Synairgen slashes costs and focuses on small hospital trials	AN
27/06	Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2023

June 27, 2024 at 11:30 am IST

Synairgen plc reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was GBP 8.41 million compared to GBP 17.65 million a year ago. Basic loss per share from continuing operations was GBP 0.0418 compared to GBP 0.0876 a year ago.

Latest news about Synairgen plc

Synairgen slashes costs and focuses on small hospital trials	27/06	AN
Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2023	27/06	CI
AstraZeneca target raised; Antofagasta lowered	07/05	AN
FTSE 100 Finishes Slightly Lower After Steady Session	11/23/11	DJ
Synairgen names Phytome's Joseph Colliver as CFO	11/23/11	AN
Biotech Company Synairgen Names New CFO	11/23/11	MT
Synairgen plc Announces Executive Changes	11/23/11	CI
Synairgen plc Announces Board Changes	11/23/11	CI
Synairgen promotes Marcin Mankowski to chief medical officer	03/23/03	AN
Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer	03/23/03	CI
Synairgen narrows interim loss on reduced R&D spending	21/23/21	AN
Earnings Flash (SNG.L) SYNAIRGEN Posts H1 Loss GBX-2.36	21/23/21	MT
Synairgen plc Reports Earnings Results for the Half Year Ended June 30, 2023	21/23/21	CI
Synairgen loss narrows; aims to develop SNG001	27/23/27	AN
Earnings Flash (SNG.L) SYNAIRGEN Reports FY22 Loss GBX-8.76	27/23/27	MT
Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
TRADING UPDATES: SulNOx raises funds; Synairgen shares trial results	23/22/23	AN
Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research	23/22/23	CI
Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee	01/22/01	CI
Synairgen Unveils Promising Phase Two Trial Results for Investigational Treatment Against COVID-19	04/22/04	MT
Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health/ Aids Clinical Trials Group-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19	04/22/04	CI
Earnings Flash (SNG.L) SYNAIRGEN Posts H1 Loss GBX-6.16	29/22/29	MT
Synairgen plc Announces Changes to Its Board	29/22/29	CI
Synairgen plc Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022	20/22/20	CI

Chart Synairgen plc

Duration

Period

More charts

Company Profile

Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.

Sector

Biotechnology & Medical Research

Calendar

26/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.0485 GBP

Average target price

0.08 GBP

Spread / Average Target

+64.95%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYNAIRGEN PLC	-18.49%	12.65M
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+44.64%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research